Previous Study: TRIO022
Next Study: BCIRG 001

Studies & Results


A randomized, multicenter, open-label, two-arm, phase II, neoadjuvant study evaluating the efficacy, safety, and pharmacokinetics of GDC-9545 plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with estrogen receptor-positive and HER2-negative untreated early breast cancer

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at